Page 41 - Risk Evaluation News Today

On February 24, 2023, the U.S. Court of Appeals for the Federal Circuit issued a precedential opinion in Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC that affirmed a...

A federal judge could soon issue a ruling that threatens access to one of two drugs commonly used in a medication abortion.

Eli Lilly’s announcement that it will cut the list price of Humulin by 70 percent before year’s end was heralded by President Joe Biden.

In the Hatch-Waxman arena of patent litigation, the crisscross of patent laws and FDA regulations is always in play. In the recent Federal Circuit decision in Jazz Pharmaceuticals, Inc....

Find information about available non-chemotherapy treatments for thyroid carcinoma, including total thyroidectomy, radiodine treatment, and ablation.

Lawsuit accuses the FDA of ignoring more than a quarter century of science showing that mifepristone is extremely safe Carson City, NV – Today, Attorney General

/PRNewswire/ -- The "Anemia And Other Blood Disorder Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.coms offering. The global...

At the start of each new Congress, The Heritage Foundation recommends pro-life policies for Members. The following year, a progress report takes stock of policy wins, ongoing challenges, and new prospects. This is the first such report in a post-Roe America. Free from the dark shadow of Roe v. Wade, Congress cannot shrink from its role in crafting policy that carries out the government’s duty to protect the first freedom: the right to life.

Federal Appeals Court Dismisses Challenge to Interim PFAS Guidance, Leaving Important Questions Unresolved - A federal appeals court dismissed a challenge to EPA's...

Ron DeSantis has helped bring the once-fringe medical freedom movement onto the national stage.